Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos

L0702000

Lisinopril dihydrate

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Lisinopril, (S)-1-[N2-(1-carboxy-3-phenylpropyl)-lysyl-proline dihydrate, MK-521

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C21H31O5N3 · 2H2O
Número CAS:
83915-83-7
Peso molecular:
441.52
Número MDL:
MFCD01698825
Código UNSPSC:
41116107
ID de substância PubChem:
329817371
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

lisinopril

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O

InChI

1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1

chave InChI

CZRQXSDBMCMPNJ-ZUIPZQNBSA-N

Informações sobre genes

human ... ACE(1636)

Procurando produtos similares? Visita Guia de comparação de produtos

Categorias relacionadas

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Lisinopril dihydrate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Ações bioquímicas/fisiológicas

Angiotensin converting enzyme (ACE) inhibitor.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

produto relacionado

Nº do produto
Descrição
Preços

1368609

Lisinopril, United States Pharmacopeia (USP) Reference Standard

Y0001234

Lisinopril impurity F, European Pharmacopoeia (EP) Reference Standard

Y0001701

Lisinopril for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001709

Lisinopril for system suitability A, European Pharmacopoeia (EP) Reference Standard

1368610

Lisinopril Related Compound A, United States Pharmacopeia (USP) Reference Standard

BP695

Lisinopril dihydrate, British Pharmacopoeia (BP) Reference Standard

PHR2239

Lisinopril Impurity A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2495

Lisinopril Impurity B, Pharmaceutical Secondary Standard; Certified Reference Material

Pictogramas

Health hazard
GHS08

Palavra indicadora

Danger

Frases de perigo

H360D,H373

Classificações de perigo

Repr. 1A - STOT RE 2

Órgãos-alvo

Kidney

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Choose from one of the most recent versions:

Certificados de análise (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Sarah J Trenfield et al.
International journal of pharmaceutics, 577, 119066-119066 (2020-01-27)
Three-dimensional printing (3DP) is a revolutionary technology in pharmaceuticals, enabling the personalisation of flexible-dose drug products and 3D printed polypills (polyprintlets). A major barrier to entry of this technology is the lack of non-destructive quality control methods capable of verifying
Manal Eid et al.
Journal of separation science, 40(18), 3646-3654 (2017-07-20)
We present an environmentally friendly method for the analysis of three angiotensin-converting enzyme inhibitors and hydrochlorothiazide simultaneously using a green micellar eluent for the first time. The chromatographic separation of enalapril maleate, lisinopril dihydrate, benazepril hydrochloride, and hydrochlorothiazide was implemented
Zhongchao Ma et al.
Human cell, 33(2), 330-336 (2020-01-19)
Renal fibrosis is a common characteristic of chronic kidney disease (CKD), and it can lead to end-stage renal disease. It has been reported that silibinin or lisinopril (MK-521) can inhibit the progression of renal fibrosis. However, the effect of combination
K L Goa et al.
Drugs, 52(4), 564-588 (1996-10-01)
Following establishment of its efficacy in hypertension and congestive heart failure, the ACE inhibitor lisinopril has now been shown to reduce mortality and cardiovascular morbidity in patients with myocardial infarction when administered as early treatment. The ability of lisinopril to
Ann Raes et al.
Journal of the renin-angiotensin-aldosterone system : JRAAS, 8(1), 3-12 (2007-05-10)
To investigate the antihypertensive efficacy, dosing, tolerability and effects on growth of lisinopril (off label-use) in paediatric patients during long-term treatment. We conducted a retrospective analysis of data from 123 patients treated with lisinopril in a paediatric nephrology clinic over
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica